Summary & Overview
HCPCS Level II Q9979: Injection, Alemtuzumab, 1 mg
HCPCS Level II code Q9979 designates a 1 mg unit of alemtuzumab for injection, a monoclonal antibody used in select immune-mediated and oncologic indications. As a HCPCS Level II drug code, Q9979 matters nationally for administration reporting, billing for infused or injected specialty therapies, and for pharmacy and therapeutic cost-tracking in outpatient settings. Accurate use affects coverage determinations, payment processing, and inventory accounting for high-cost biologic agents.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise clinical context for alemtuzumab injections, the expected service settings (infusion centers and outpatient clinics), and guidance on the types of benchmarks and policy items typically associated with HCPCS drug units—such as dosing unitization, site-of-service implications, and payer coverage considerations. The publication outlines what to expect from payer coverage rules, how unit-based HCPCS codes feed into reimbursement and patient cost-sharing calculations, and where to look for updates on drug-specific policy changes. Data not available in the input will be clearly identified in relevant sections.
Billing Code Overview
HCPCS Level II code Q9979 represents injection, alemtuzumab, 1 mg. This code denotes the drug product unit for alemtuzumab administered by injection.
-
Service type: Drug administration (injectable monoclonal antibody)
-
Typical site of service: Infusion center, outpatient clinic, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsing forms of multiple sclerosis (MS) or other approved lymphocyte-mediated autoimmune conditions being considered for treatment with alemtuzumab. The patient is referred to an infusion center by a neurologist after prior therapies failed or were contraindicated. Before the first infusion, baseline labs (CBC, CMP, thyroid panel, viral serologies) and infection screening are completed; vaccination status is reviewed. The initial alemtuzumab dosing occurs in an outpatient infusion suite or hospital outpatient department where pre-medications (e.g., corticosteroid, antihistamine, antipyretic) are administered and vital signs are monitored. The infusion of Q9979 (alemtuzumab, 1 mg per billing unit) is documented with lot numbers, total milligrams given, start/stop times, and any infusion reactions. Follow-up includes laboratory monitoring for immune-mediated adverse events and scheduling of subsequent treatment courses per the medication’s dosing schedule. Typical sites of service are outpatient infusion center, ambulatory surgery center (if arranged for medication administration), or hospital outpatient department depending on clinical complexity and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |